Sort by: after hours % change | delayed % change | gain open | gain high | gain close | publishing date
symbols : Mrk source : Www.biospace.com save search
Health Canada Approves KEYTRUDA as a first-line treatment for adult patients with locally advanced unresectable or metastatic HER2-negative gastric or gastroesophageal junction (GEJ) adenocarcinoma
Published: 2024-04-19 (Crawled : 13:00) - biospace.com/
MRK | News | $125.78 0.44% 0.0% 8.4M
|
Health Technology
|
| O: 0.22%
H: 0.37%
C: 0.1%
health treatment for canada advanced keytruda
Merck Initiates Phase 3 Clinical Trial of MK-1084, an Investigational Oral KRAS G12C Inhibitor, in Combination with KEYTRUDA® (pembrolizumab) for First-Line Treatment of Certain Patients With Metastatic Non-Small Cell Lung Cancer
Published: 2024-04-04 (Crawled : 12:00) - biospace.com/
MRK | News | $125.78 0.44% 0.0% 8.4M
|
Health Technology
|
| O: 0.24%
H: 0.08%
C: -2.42%
mk-1084 keytruda lung merck cancer cell treatment trial
REJOICE-Ovarian01 Phase 2/3 Trial of Raludotatug Deruxtecan Initiated in Patients with Platinum-Resistant Ovarian Cancer
Published: 2024-04-03 (Crawled : 13:00) - biospace.com/
MRK | News | $125.78 0.44% 0.0% 8.4M
|
Health Technology
|
| O: 0.13%
H: 0.0%
C: 0.0%
cancer trial initiated
Merck to Hold First-Quarter 2024 Sales and Earnings Conference Call April 25
Published: 2024-04-01 (Crawled : 12:00) - biospace.com/
MRK | News | $125.78 0.44% 0.0% 8.4M
|
Health Technology
|
| O: -0.23%
H: 0.19%
C: -0.52%
sales conference merck
European Commission Approves Merck’s KEYTRUDA® (pembrolizumab) Plus Chemotherapy as Neoadjuvant Treatment, Then Continued as Monotherapy as Adjuvant Treatment, for Resectable Non-Small Cell Lung Cancer at High Risk of Recurrence in Adults
Published: 2024-03-28 (Crawled : 11:00) - biospace.com/
MRK | News | $125.78 0.44% 0.0% 8.4M
|
Health Technology
|
| O: 0.18%
H: 0.0%
C: 0.0%
keytruda lung cancer cell risk plus
Merck Foundation Strengthens Its Commitment to Expanding Access to Care in Asia-Pacific Region
Published: 2024-03-26 (Crawled : 00:00) - biospace.com/
MRK | News | $125.78 0.44% 0.0% 8.4M
|
Health Technology
|
| O: 0.38%
H: 0.24%
C: -0.21%
merck care foundation
FDA Approves Merck’s WINREVAIR™ (sotatercept-csrk), a First-in-Class Treatment for Adults with Pulmonary Arterial Hypertension (PAH, WHO* Group 1)
Published: 2024-03-26 (Crawled : 23:00) - biospace.com/
MRK | News | $125.78 0.44% 0.0% 8.4M
|
Health Technology
|
| O: 0.38%
H: 0.24%
C: -0.21%
fda group treatment hypertension
Merck Provides Update on Phase 3 KEYLYNK-006 Trial Evaluating KEYTRUDA® (pembrolizumab) Plus Maintenance LYNPARZA® (olaparib) for Certain Patients With Metastatic Nonsquamous Non-Small Cell Lung Cancer
Published: 2024-03-21 (Crawled : 12:00) - biospace.com/
MRK | News | $125.78 0.44% 0.0% 8.4M
|
Health Technology
|
| O: -0.13%
H: 0.4%
C: -0.06%
ylynk-006 keytruda lung merck update cancer cell trial plus
Merck Announces Positive Data on V116, an Investigational, 21-Valent Pneumococcal Conjugate Vaccine Specifically Designed for Adults, Demonstrated Immune Responses in Adults
Published: 2024-03-19 (Crawled : 13:30) - biospace.com/
MRK | News | $125.78 0.44% 0.0% 8.4M
|
Health Technology
|
| O: 0.0%
H: 0.68%
C: 0.63%
pneumococcal vaccine merck positive
Merck’s KEYTRUDA® (pembrolizumab) Plus Chemoradiotherapy (CRT) Significantly Improved Overall Survival (OS) Versus CRT Alone in Patients With Newly Diagnosed High-Risk Locally Advanced Cervical Cancer
Published: 2024-03-15 (Crawled : 11:00) - biospace.com/
MRK | News | $125.78 0.44% 0.0% 8.4M
|
Health Technology
|
| O: -0.56%
H: 1.75%
C: 1.4%
keytruda cancer alone advanced plus
Merck Announces Plans to Conduct Clinical Trials of a Novel Investigational Multi-Valent Human Papillomavirus (HPV) Vaccine and Single-Dose Regimen for GARDASIL®9
Published: 2024-03-13 (Crawled : 11:00) - biospace.com/
MRK | News | $125.78 0.44% 0.0% 8.4M
|
Health Technology
|
| O: 0.41%
H: 0.04%
C: -0.81%
gardasil vaccine merck trials
Merck Completes Acquisition of Harpoon Therapeutics, Inc.
Published: 2024-03-11 (Crawled : 16:00) - biospace.com/
MRK | News | $125.78 0.44% 0.0% 8.4M
|
Health Technology
|
| O: 0.93%
H: 0.0%
C: -1.51%
merck acquisition
Ligand Reports Fourth Quarter and Full Year 2023 Financial Results
Published: 2024-02-27 (Crawled : 13:00) - biospace.com/
TVTX | $5.73 -1.21% -1.22% 950K
|
Health Technology
|
| O: 2.37%
H: 1.46%
C: 1.22%
MRK | News | $125.78 0.44% 0.0% 8.4M
|
Health Technology
|
| O: -0.45%
H: 0.7%
C: 0.6%
HTGC F | $18.46 1.15% 0.38% 660K
|
Finance
|
| O: -2.77%
H: 0.47%
C: -0.27%
VKTX | $63.38 -2.0% -2.04% 3M
|
Health Technology
|
| O: 81.31%
H: 29.0%
C: 21.9%
VRNA | $15.82 -1.74% -1.83% 640K
|
Health Technology
|
| O: 2.1%
H: 2.83%
C: -0.5%
LGND | $72.59 0.1% 0.1% 140K
|
Health Technology
|
| O: 14.46%
H: 11.02%
C: 4.72%
ALDX | $3.865 -2.89% -2.98% 430K
|
Health Technology
|
| O: 1.91%
H: 2.68%
C: 1.07%
year financial results
MERCK CANADA ANNOUNCES COLLABORATION WITH VECTOR INSTITUTE TO FURTHER ADVANCE ITS ARTIFICIAL INTELLIGENCE CAPABILITIES AND DRIVE INNOVATION IN HEALTHCARE
Published: 2024-02-08 (Crawled : 13:30) - biospace.com/
MRK | News | $125.78 0.44% 0.0% 8.4M
|
Health Technology
|
| O: -0.12%
H: 0.13%
C: -0.56%
institute intelligence merck innovation collaboration canada
Merck Announces Fourth-Quarter and Full-Year 2023 Financial Results
Published: 2024-02-01 (Crawled : 23:00) - biospace.com/
SNYNF | News | $92.7 -2.18% 600K
|
Health Technology
|
| O: -4.37%
H: 0.0%
C: 0.0%
MRK | News | $125.78 0.44% 0.0% 8.4M
|
Health Technology
|
| O: 2.38%
H: 2.25%
C: 2.21%
SNY | News | $46.32 2.05% 2.01% 3.3M
|
Health Technology
|
| O: -5.26%
H: 0.0%
C: 0.0%
MRNA S | $101.44 -0.55% -0.55% 2.6M
|
Health Technology
|
| O: -0.15%
H: 0.1%
C: -1.86%
HARP | $23.01 0.07% 6.6M
|
Health Technology
|
| O: 0.0%
H: 0.0%
C: 0.0%
merck financial results
Merck’s KEYTRUDA® (pembrolizumab) Significantly Improved Disease-Free Survival (DFS) as Adjuvant Therapy Versus Observation in High-Risk Patients With Localized Muscle-Invasive and Locally Advanced Urothelial Carcinoma After Surgery
Published: 2024-01-26 (Crawled : 23:00) - biospace.com/
MRK | News | $125.78 0.44% 0.0% 8.4M
|
Health Technology
|
| O: 0.32%
H: 0.42%
C: 0.26%
keytruda advanced therapy
Merck to Hold Fourth-Quarter and Full-Year 2023 Sales and Earnings Conference Call Feb. 1
Published: 2024-01-19 (Crawled : 14:00) - biospace.com/
MRK | News | $125.78 0.44% 0.0% 8.4M
|
Health Technology
|
| O: -0.28%
H: 0.68%
C: 0.58%
sales conference merck
Merck Announces Phase 3 Trial Initiations for Four Investigational Candidates From its Promising Hematology and Oncology Pipeline
Published: 2024-01-05 (Crawled : 22:00) - biospace.com/
MRK | News | $125.78 0.44% 0.0% 8.4M
|
Health Technology
|
| O: 0.08%
H: 0.29%
C: 0.1%
merck pipeline trial
Merck Provides U.S. Regulatory Update on Gefapixant
Published: 2023-12-20 (Crawled : 00:00) - biospace.com/
MRK | News | $125.78 0.44% 0.0% 8.4M
|
Health Technology
|
| O: 0.61%
H: 0.0%
C: -1.66%
merck update
European Commission Approves Merck’s KEYTRUDA® (pembrolizumab) Plus Chemotherapy for New First-Line Indications in Advanced HER2-Negative Gastric or GEJ Adenocarcinoma in Tumors
Published: 2023-12-18 (Crawled : 14:00) - biospace.com/
MRK | News | $125.78 0.44% 0.0% 8.4M
|
Health Technology
|
| O: 1.0%
H: 0.99%
C: -0.11%
keytruda tumors advanced plus
Gainers vs Losers
| 67% | 33% |
Top 10 Gainers
Your saved searches
Save your searches and get alerts when important news are released.